Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Eighteen analysts cover Summit Therapeutics with a consensus rating of Moderate Buy (2 sell, 5 hold, 9 buy, 2 strong buy) and an average 12‑month price target of $31.00.
• Recent analyst activity is mixed but constructive: Stifel initiated coverage with a buy and a $45 target, Citigroup started with a buy, HC Wainwright trimmed its target to $30 while keeping a buy, and Zacks upgraded the stock to hold from strong sell.
• Shares trade around $22.08 (12‑month range $13.83–$35.92) with a market cap of $17.14B; the company reported an EPS miss last quarter (‑$0.29 vs. ‑$0.22 est.) and analysts expect roughly ‑1.31 EPS for the year.

Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $31.00.

Several brokerages recently commented on SMMT. Stifel Nicolaus initiated coverage on shares of Summit Therapeutics in a research report on Wednesday, April 8th. They set a "buy" rating and a $45.00 price target for the company. HC Wainwright lowered their price objective on shares of Summit Therapeutics from $40.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 24th. Citigroup started coverage on Summit Therapeutics in a research report on Wednesday, April 8th. They issued a "buy" rating on the stock. Citizens Jmp reiterated a "market outperform" rating and issued a $40.00 target price on shares of Summit Therapeutics in a report on Friday, January 30th. Finally, Zacks Research raised Summit Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Thursday, March 5th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Summit Therapeutics in the 4th quarter valued at about $28,000. Crowley Wealth Management Inc. lifted its stake in shares of Summit Therapeutics by 66.7% in the third quarter. Crowley Wealth Management Inc. now owns 1,500 shares of the company's stock worth $31,000 after acquiring an additional 600 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Summit Therapeutics by 2,654.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,873 shares of the company's stock worth $33,000 after acquiring an additional 1,805 shares in the last quarter. Parallel Advisors LLC purchased a new position in Summit Therapeutics in the third quarter valued at about $39,000. Finally, Truvestments Capital LLC grew its stake in Summit Therapeutics by 200.2% during the 4th quarter. Truvestments Capital LLC now owns 2,603 shares of the company's stock valued at $46,000 after purchasing an additional 1,736 shares in the last quarter. 4.61% of the stock is owned by hedge funds and other institutional investors.

Summit Therapeutics Price Performance

SMMT opened at $22.08 on Friday. Summit Therapeutics has a 12 month low of $13.83 and a 12 month high of $35.92. The business has a 50-day moving average of $17.96 and a two-hundred day moving average of $17.89. The stock has a market capitalization of $17.14 billion, a price-to-earnings ratio of -15.23 and a beta of -1.36.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.07). Equities research analysts anticipate that Summit Therapeutics will post -1.31 earnings per share for the current year.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.